M3 Wake Research is a well-established, privately held clinical research organization (CRO) site network that has been operating for over 30 years. As a wholly-owned subsidiary of the Japanese digital health giant M3, Inc., it leverages a unique integrated model of owned and operated research sites to efficiently recruit participants and conduct trials for industry sponsors. The company has demonstrated significant scale, having completed 674 studies and enrolled over 19,000 participants in the last five years across numerous therapeutic indications. Its business model is centered on providing clinical trial services, positioning it as a critical execution partner in the drug development value chain.
Alzheimer'sAutoimmune DisordersCardiologyDermatologyGastric HealthHepatology / NephrologyNeurology / PsychiatryObesityOncology / HematologyOrthopedicsPulmonologyType 1 & Type 2 DiabetesVaccines / PreventionWomen's Health
Technology Platform
An integrated, wholly-owned network of physical clinical research sites with standardized operational protocols for patient recruitment, retention, and trial execution. Leverages potential synergies with parent company M3's digital health platforms for engagement and data management.
Funding History
1
UndisclosedUndisclosedM3, Inc.
Opportunities
The growing global clinical trials market and chronic industry challenges in patient recruitment present a major opportunity for efficient site networks.
The trend towards decentralized trials and demand for greater participant diversity allows M3 Wake Research to leverage its integrated site model and community connections.
Synergies with M3's digital health tools can enhance recruitment and trial operations.
Risk Factors
Faces intense competition from other site networks and CROs.
Revenue is dependent on the cyclical R&D spending of biopharma sponsors.
Operational risks, such as recruitment delays or data issues, can damage client relationships.
Regulatory changes in clinical research pose ongoing compliance challenges.
Competitive Landscape
M3 Wake Research competes with other large dedicated site networks (e.g., CenExel, Velocity Clinical Research), the site management arms of global CROs (e.g., IQVIA, Syneos Health, PPD), and a vast ecosystem of independent clinical trial sites. Its key differentiators are its scale as an integrated, owned network, its 30+ year track record, and the strategic backing of digital health parent M3, Inc.
